Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-453 | Tivantinib | MET | RTK | 0.20059 | -0.0719 | 0.4182 | 0.1017 | 2.2407 | 0.20744 | 0.99393 |
MDA-MB-453 | Cediranib | VEGFR/cKIT | RTK | 2.7824 | -0.6894 | 0.1569 | 0.0768 | 3.0858 | 3.7659 | 0.99464 |
MDA-MB-453 | Cabozantinib | VEGFR2/MET | RTK | 9.0899 | 0.4645 | -0.0045 | 0.0208 | 4.5355 | 6.5788 | 0.94161 |
MDA-MB-468 | Abemaciclib | CDK4/6 | Cell cycle | 2.3386 | -0.2881 | 0.1766 | 0.0681 | 1.5630 | 3.8065 | 0.9935 |
MDA-MB-468 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0457 | -0.0214 | 0.0005 | 0.0000 | Inf | -0.58792 |
MDA-MB-468 | AZD7762 | CHK1/2 | Cell cycle | 0.28495 | -0.5860 | 0.4932 | 0.2129 | 1.0622 | 0.63742 | 0.99549 |
MDA-MB-468 | Volasertib | PLK | Cell cycle | 0.002104 | -0.4485 | 0.9279 | 0.3934 | 2.9173 | 0.0026072 | 0.99938 |
MDA-MB-468 | Dinaciclib | pan CDK | Cell cycle | 0.015576 | -0.4131 | 0.5681 | 0.1843 | 2.8840 | 0.018635 | 0.99641 |
MDA-MB-468 | Cisplatin | Chemo | Chemotherapy | 1.2638 | -0.2866 | 0.2872 | 0.0977 | 1.4057 | 1.9559 | 0.99503 |
MDA-MB-468 | Doxorubicin | Chemo | Chemotherapy | 0.0054214 | -0.3392 | 0.9121 | 0.3191 | 2.4137 | 0.0067542 | 0.99424 |
MDA-MB-468 | Taxol | Chemo | Chemotherapy | 0.001354 | -0.5218 | 1.0076 | 0.5243 | 1.2795 | 0.0023644 | 0.95471 |
MDA-MB-468 | Topotecan | Topo I | Chemotherapy | 0.015779 | -0.6577 | 1.0692 | 0.4464 | 2.1036 | 0.023029 | 0.99528 |
MDA-MB-468 | Etoposide | Topo II | Chemotherapy | 0.48754 | -0.5132 | 0.4291 | 0.1644 | 1.8475 | 0.69756 | 0.99577 |
MDA-MB-468 | Dasatinib | BCR/ABL | MAPK/nRTK | 4.4311 | 0.3393 | 0.1447 | 0.0458 | 0.7091 | 5.6436 | 0.97277 |
MDA-MB-468 | Trametinib | MEK | MAPK/nRTK | 0.4421 | 0.4075 | 0.2132 | 0.0255 | 0.4592 | 0.27448 | 0.99227 |
MDA-MB-468 | Saracatinib | SRC | MAPK/nRTK | 4.9591 | 0.1778 | 0.1388 | 0.0508 | 0.9811 | 15.1962 | 0.9691 |
MDA-MB-468 | ABT-737 | Bcl2/XL | Misc | 6.0269 | 0.1420 | 0.0860 | 0.0547 | 1.5887 | 12.0342 | 0.98897 |
MDA-MB-468 | Vorinostat | HDAC | Misc | 1.5734 | -0.1191 | 0.2172 | 0.0608 | 1.9840 | 1.8053 | 0.99971 |
MDA-MB-468 | Luminespib | HSP90 | Misc | 0.0048347 | -0.1738 | 0.6478 | 0.1563 | 4.7025 | 0.0051177 | 0.99878 |
MDA-MB-468 | A-1210477 | Mcl-1 | Misc | Inf | 0.9299 | 0.0206 | 0.0057 | 0.3898 | 963.6809 | 0.60314 |
MDA-MB-468 | Olaparib | PARP | Misc | 7.9202 | 0.3408 | 0.0576 | 0.0179 | 1.6505 | 15.4105 | 0.98176 |
MDA-MB-468 | Bleomycin | Radiation | Misc | 0.82322 | -0.2103 | 0.3246 | 0.1050 | 0.8733 | 1.7869 | 0.99409 |
MDA-MB-468 | Ipatasertib | AKT | PI3K/mTOR | 2.3697 | 0.3091 | 0.2229 | 0.0266 | 0.5702 | 1.4742 | 0.96355 |
MDA-MB-468 | Alpelisib | PI3Ka | PI3K/mTOR | 15.9683 | 0.7142 | 0.0314 | 0.0171 | 1.4955 | 33.2195 | 0.92719 |
MDA-MB-468 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 2.3526 | 0.0046 | 0.2170 | 0.0736 | 0.6960 | 11.4039 | 0.97997 |